Natco Pharma Share Price Rises 0.36% to Rs 885.70 Despite USFDA Issuing Four Observations at Visakhapatnam FDF Plant

What Is the Natco Pharma USFDA Inspection at Visakhapatnam?

The US Food and Drug Administration conducted an inspection at Natco Pharma's Finished Dosage Formulations (FDF) manufacturing plant located in Visakhapatnam, Andhra Pradesh, from August 17 to August 21, 2026. Following the inspection, the US FDA issued a Form 483 with four observations. Natco Pharma has stated that the observations are procedural in nature.

A Form 483 is issued by the FDA at the conclusion of an inspection when investigators observe conditions that may constitute violations of the Food, Drug, and Cosmetic Act. The company now has the opportunity to respond to the FDA with corrective action plans within the standard response timeline.

Click Here – Get Free Investment Predictions

Natco Pharma Share Price and Inspection Details

Parameter	Detail
Facility Inspected	FDF Manufacturing Plant, Visakhapatnam, Andhra Pradesh
Inspection Dates	August 17 to 21, 2026
Regulatory Document Issued	Form 483
Number of Observations	Four
Nature of Observations	Procedural (per company disclosure)
CMP (24 Aug)	Rs 885.70 (+0.36%)
Intraday High	Rs 892.40
Intraday Low	Rs 876.90

Why Did Natco Pharma Share Price Rise Despite FDA Observations?

Natco Pharma share price rising 0.36% despite the disclosure of FDA observations reflects the market's assessment that procedural Form 483 observations are a routine and manageable part of operating in the heavily regulated US generics and pharmaceutical export business. Unlike a Warning Letter or an Official Action Indicated (OAI) classification, procedural observations at the Form 483 stage typically do not disrupt ongoing manufacturing operations or export approvals from the facility in question.

Investors should note that trading volume today was 28,276 shares, slightly below the five-day average of 30,983 shares, an 8.74% decrease, suggesting the market has not reacted with elevated urgency to the FDA disclosure.

Screen Natco Pharma on Univest Screener for USFDA Compliance Track Record

About Natco Pharma: Business Overview

Natco Pharma is a leading Indian pharmaceutical company known for its complex generics portfolio, oncology drug franchise, and active pharmaceutical ingredient (API) manufacturing capabilities. The company has multiple manufacturing facilities across India that are certified by the US FDA and other global regulatory bodies, supplying finished dosage formulations to the US and other regulated markets. Given the importance of USFDA-approved manufacturing capacity to Natco Pharma's revenue base, the company's regulatory compliance track record is a key monitoring point for investors.

Download the Univest iOS App or Univest Android App to track Natco Pharma share price and USFDA regulatory updates live.

Conclusion

Natco Pharma share price rose 0.36% to Rs 885.70 on August 24, 2026, despite the company disclosing four USFDA observations at its Visakhapatnam FDF manufacturing plant following an inspection from August 17 to 21. The company has characterised the observations as procedural in nature, and the muted market reaction suggests investors view this as a manageable regulatory matter. Monitor for the company's formal response to the FDA and any subsequent regulatory classification. Verify all data on NSE and BSE before making any investment decisions.

Frequently Asked Questions

What is the Natco Pharma USFDA inspection at Visakhapatnam?

Ans. The US FDA inspected Natco Pharma's Finished Dosage Formulations (FDF) manufacturing plant in Visakhapatnam, Andhra Pradesh, from August 17 to 21, 2026, and issued a Form 483 with four observations, which the company has described as procedural in nature.

What is Natco Pharma share price today?

Ans. Natco Pharma was trading at Rs 885.70 on August 24, 2026, up 0.36% or Rs 3.20. Intraday high was Rs 892.40 and intraday low was Rs 876.90.

Why did Natco Pharma share price rise despite FDA observations?

Ans. Natco Pharma share price rose modestly despite the FDA observations because the market assesses procedural Form 483 observations as routine and manageable, unlike a more serious Warning Letter or OAI classification. Trading volume was also slightly below average, suggesting limited market urgency.

What is a Form 483 in FDA inspections?

Ans. A Form 483 is a document issued by the US FDA at the conclusion of an inspection when investigators observe conditions that may constitute violations of the Food, Drug, and Cosmetic Act. Companies have the opportunity to respond with corrective action plans within a standard timeline.

What is Natco Pharma's business?

Ans. Natco Pharma is a leading Indian pharmaceutical company known for its complex generics portfolio, oncology drug franchise, and API manufacturing. It operates multiple USFDA-certified manufacturing facilities supplying finished dosage formulations to regulated global markets.

Is Natco Pharma a good buy after the USFDA observations?

Ans. This article is for educational purposes only and is not investment advice. Procedural observations are generally manageable, but investors should monitor the company's formal FDA response and any subsequent regulatory classification changes. Consult a SEBI-registered advisor before investing.